{"disease":{"id":"gaucher-disease","name":"gaucher disease"},"drugs":{"marketed":[{"drug_id":"taliglucerase-alfa","indication_name":"Type 1 Gaucher Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TALIGLUCERASE ALFA","company_name":"","drug_phase":"marketed","molecular_target":"glucocerebrosidase","drug_class":"Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC]","quality_score":45,"revenue":null,"mechanism":"ELELYSO replaces deficient glucocerebrosidase, reducing glucocerebroside accumulation in Gaucher cells."},{"drug_id":"glucocerebrosidase","indication_name":"Chronic non-neuropathic Gaucher's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"glucocerebrosidase","company_name":"National Center for Research Resources (NCRR)","drug_phase":"phase_2","molecular_target":"","drug_class":"","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"elelyso","indication_name":"Type 1 Gaucher disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Elelyso","generic_name":"Taliglucerase Alfa","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Glucocerebroside (substrate); mannose receptors on cell surface","drug_class":"Enzyme replacement therapy","quality_score":10,"revenue":null,"mechanism":"Recombinant glucocerebrosidase enzyme replacement therapy that catalyzes hydrolysis of glucocerebroside to glucose and ceramide."},{"drug_id":"alglucerase","indication_name":"Chronic non-neuropathic Gaucher's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceredase","generic_name":"ALGLUCERASE","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glucocerebroside-specific Enzyme","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"velaglucerase-alfa","indication_name":"Chronic non-neuropathic Gaucher's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vpriv","generic_name":"VELAGLUCERASE ALFA","company_name":"Shire Human Genetic","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC]","quality_score":50,"revenue":null,"mechanism":"VELAGLUCERASE ALFA replaces the deficient enzyme glucocerebrosidase in patients with Gaucher's disease."}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05368038","title":"ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Albert Einstein College of Medicine","has_results":false},{"nct_id":"NCT00358943","title":"International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT03291223","title":"Gaucher Disease Outcome Survey (GOS)","phase":"","overall_status":"RECRUITING","enrollment_count":1257,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT06539169","title":"FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT00001215","title":"Genetic Studies of Lysosomal Storage Disorders","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1000,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT05253560","title":"Prodromal Parkinsonian Features in GBA1 Mutation Carriers","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Shaare Zedek Medical Center","has_results":false},{"nct_id":"NCT06573723","title":"Institutional Registry of Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":380,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT04388969","title":"World Data on Ambroxol for Patients With GD and GBA Related PD","phase":"","overall_status":"UNKNOWN","enrollment_count":300,"lead_sponsor_name":"Shaare Zedek Medical Center","has_results":false},{"nct_id":"NCT02416661","title":"Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease","phase":"","overall_status":"COMPLETED","enrollment_count":299,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT05619900","title":"Registry of Patients Diagnosed With Lysosomal Storage Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT03240653","title":"Gaucherite - A Study to Stratify Gaucher Disease","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Cambridge University Hospitals NHS Foundation Trust","has_results":false},{"nct_id":"NCT04470713","title":"Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2","phase":"","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Idorsia Pharmaceuticals Ltd.","has_results":false},{"nct_id":"NCT04758130","title":"Getting Global Rare Disease Insights Through Technology Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"M.A.G.I.C. Clinic LTD","has_results":false},{"nct_id":"NCT05702814","title":"A Study Measuring Substances Potentially Indicating Bone Problems in Adults With Type 1 Gaucher Condition","phase":"","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT05641103","title":"PREDIGA 2: Spanish Acronym of \"Educational and Diagnostic Project for Gaucher and ASMD\"","phase":"","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Fundación Española de Hematología y Hemoterapía","has_results":false},{"nct_id":"NCT00635427","title":"An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT01417520","title":"Clinical and Pathophysiological Investigations Into Erdheim Chester Disease","phase":"","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT04997772","title":"Digital Health Platform Customized for Patients With Gaucher Disease","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Shoshana Vilk","has_results":false},{"nct_id":"NCT02785744","title":"Genzyme Osteopenia/Osteoporosis Study","phase":"","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT00001289","title":"Effects of Enzyme Replacement in Gaucher's Disease","phase":"","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT00302146","title":"Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations","phase":"","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"National Human Genome Research Institute (NHGRI)","has_results":false},{"nct_id":"NCT03625882","title":"Survey Study for Velaglucerase Alfa (VPRIV) in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04845958","title":"A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05536388","title":"Drug Discovery for Parkinson's With Mutations in the GBA Gene","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT05669729","title":"A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT03485677","title":"Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06258577","title":"Screening for Gaucher Disease and Acid Sphingomyelinase Deficiency","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Chung-Hsing Wang","has_results":false},{"nct_id":"NCT00465062","title":"A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT07223944","title":"A Gaucher Disease Gene Therapy Trial With FLT201","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Spur Therapeutics","has_results":false},{"nct_id":"NCT05816993","title":"Assessment of Neurological Manifestations in Gaucher Disease Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":45,"lead_sponsor_name":"Assiut University","has_results":false},{"nct_id":"NCT06627543","title":"Effect of Enzyme Replacement Therapy on Cardiac Function in Children With Gaucher Disease Type 3","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":44,"lead_sponsor_name":"Noha Osman","has_results":false},{"nct_id":"NCT05222906","title":"Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT04787887","title":"A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"ISU Abxis Co., Ltd.","has_results":false},{"nct_id":"NCT00319046","title":"Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Actelion","has_results":true},{"nct_id":"NCT05447494","title":"Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"CANbridge (Suzhou) Bio-pharma Co., Ltd.","has_results":false},{"nct_id":"NCT04055831","title":"Immune Biomarkers Related to Bone Pathology in Patients With Type 1 Gaucher Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Lysosomal and Rare Disorders Research and Treatment Center, Inc.","has_results":false},{"nct_id":"NCT00478647","title":"Study of GA-GCB Enzyme Replacement Therapy in Type 1 Gaucher Disease Patients Previously Treated With Imiglucerase","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT03950050","title":"Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Shaare Zedek Medical Center","has_results":false},{"nct_id":"NCT06211478","title":"Role of Vitamin E in Gaucher Disease Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Ain Shams University","has_results":false},{"nct_id":"NCT03746587","title":"Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":39,"lead_sponsor_name":"ZevraDenmark","has_results":false},{"nct_id":"NCT00553631","title":"Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Shire","has_results":true},{"nct_id":"NCT01356537","title":"Home Therapy With VPRIV in Gaucher's Disease","phase":"","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT02536755","title":"Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Completed Phase 2 or Phase 3 Studies","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":true},{"nct_id":"NCT00041535","title":"OGT 918-006: A Phase I/II Randomized, Controlled Study of OGT 918 in Patients With Neuronopathic Gaucher Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT04353466","title":"Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Shaare Zedek Medical Center","has_results":false},{"nct_id":"NCT00433147","title":"A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT05843552","title":"Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT04101968","title":"The GBA Multimodal Study in Parkinson's Disease","phase":"","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Pacific Parkinson's Research Centre","has_results":false},{"nct_id":"NCT00430625","title":"A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Shire","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}